First of all, we evaluated TGF-β1 content in the obtained serum samples and found that MDS contained about 95 ng/ml TGF-β1, which is enough to induce transformation of SCs into myofibroblasts according to in vitro protocols typically requiring not more than 10 ng/ml. This evidence concerns the gene TGFB1 and myelodysplastic syndrome.